Importance of hormone receptors in breast cancer
Abstract
The basis of the diagnosis of breast cancer is the histological confirmation of it. In the diagnostic methods performed on biopsy specimens and / or surgical specimens of patients, analysis of hormone receptors, provides information to the appropriate prescription of the endocrine treatments used today, in addition to having utility as a prognostic factor in determining the risk of recurrence post treatment and evaluate the response. To obtain tumor tissue, also allows to determine prognostic and predictive factors such as histopathological classification of the tumor, its size, number of positive lymph nodes and lymph-vascular commitment, all of them very important in a integrated treatment, in order to improve the quality and life expectancy of patients.Downloads
References
Brachtel, Elena. Molecular Pathology of the Breast. En: Surgical Pathology Clinics. Vol 5, Issue 4 December 2012 p. 793–819. ELSEVIER. Disponible en: http://dx.doi.org/10.1016/j.path.2012.08.001. [mayo, 31, 2013].
Organización Mundial De La Salud. Cáncer de mama: prevención y control. 2013 [En línea] disponible en: http://www.who.int/topics/cáncer/breastcáncer/es/index1.html. [mayo, 30, 2013].
Unión Latinoamericana Contra El Cáncer De La Mujer. Resumen del reporte del cáncer de mama en América
Latina. [En línea] Disponible en: http://ulaccam.org/wp-content/uploads/2012/03/Resumen-del-reporte-Cáncer-de-mama-en-America-Latina.pdf. [abril, 25, 2013].
Instituto Nacional De Cáncerología. Grupo Vigilancia Epidemiológica del Cáncer. Tabla 83, Cáncer de mama. Incidencia estimada según departamentos, Colombia, 2002-2006.
Jatoi, Miller. Why is breast-cancer mortality declining? Lancet Oncol 4: 251–254. 2003.
Duffy, M.J. Estrogens receptors: role in Breast Cáncer. Critical Reviews in Clinical Laboratory Sciences; 2006; 43, 4; ProQuest pg. 325. 7 Hunter DJ, Colditz GA, Hankinson SE, Malspeis, SpiegelmanD,
Chen W, et al. Oral contraceptive use and breast cáncer: a prospective study of young women. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. PubMed: http://www.ncbi.nlm.nih.gov/pubmed/20802021. [Junio, 17, 2013]
lemons M, Goss, P. Estrogen and the risk of breast cancer. Londres NEngl J Med, 2001.p.276–285
Collaborative Group on Hormonal Factors in Breast Cancer: Secretariat, Cáncer Epidemiology Unit, Building R. Menarche, menopause, and breast cáncer risk: individual participant meta-analysis, including 118 964 women with breast cáncer from 117 epidemiological studies. Oxford, Lancet Oncol 2012; 13: 1141–51.
Christine B, Simone B, Gerald F, Helena M, Verkooijen, Pierre O, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat; 2011 127:233–241.
Garcia Y. Receptores de estrógeno: estructura, mecanismo de acción y su relación con en el desarrollo de embriones de mamíferos en la etapa de preimplantación. Boletín Médico de Postgrado. Vol. XXV Edición Especial Año 2009 UCLA. Decanato de Medicina. Barquisimeto – Venezuela.
Sartorius C, Shen T & Horwitz, K. B. (2003). Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Research and Treatment, 79(3), 287-99.
Althuis MD et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers 2004; 13 (10):1558–68.
Pérez, V, Vela, T, Mora, A. Diagnóstico Histopatológico y Factores Pronósticos en Cáncer Infiltrante de Glándula Mamaria. Cancerología Mexico DF, 2008. p. 7-17.
Mahmoud R. Hussein, Saad R.A.H. Abd-Elwahed, Ahmad Rezk Abdulwahed. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biology International 2008 (32). p. 698 - 707.
Sunil R. Lkhani, Ian O. Ellis, Stuart J. Schinitt. WHO Classification of Tumours of the Breast. International Agency for Research on Cáncer. Lyon, 2012. 4th Edition World Health Organization Classification of Tumours.
Federation of European Biochemical Societies. Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. Madrid, España.
Rubin R, Strayer D, Rubin E. Rubin, Patología Fundamentos Clínico-patológicos en Medicina. Sexta Edición.
Wolters Kluwer Health España S.A., Lippincott Williams & Wilkins, 2012. p 933-935.
Kumar V, Abbas A, Fausto N, Aster J. Robbins y Cotran, Patología Estructural y Funcional. 8ª ed. Madrid (Esp.): Elsevier, 2010. p 1084-1085
Jones R, Constantinidou A, Reis-filhoJ. Molecular classification of breast cáncer. En: Surgical Pathology 5. Elsevier, 2012. p. 701–717.
Rosen, P. Breast Pathology Diagnosis by Needle Core Biopsy. Philadelphia (E.U.): Lippincott Williams & Wilkins, 1999. p. 95.
Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006; 49:22–34.
Hammond ME, Hayes DF, Dowsett M, Allred DC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cáncer. Arch Pathol Lab Med 2010;134(6):907-22)
Pracella D, Bonin S, Barbazza R, Sapino A, Castellano I, Sulfaro S, and Stanta G. Clinical Study. Are Breast Cáncer Molecular Classes Predictive of Survival in Patients with Long Follow-Up?. Hindawi Publishing Corporation Disease Markers 2013; 35(6): 595–605.
S. Guiu, S. Michiels, F. André, J. Cortes, C. Denkert, A. Di Leo, et al. Reviews. Molecular subclasses of breast cáncer: how do we define them? The IMPAKT Working Group Statement. Annals of Oncology 2012; 23: 299
.png)
